Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.27.4 (
ribonuclease
)
6,621
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The rat
insulin-like growth factor II
(rIGF-II) gene, which exists as a single copy in the genome, is expressed as a multitranscript family of mRNA molecules ranging in size from 4.6 to 1 kilobases. Part of this heterogeneity can be ascribed to the presence of two different promoters, each transcribing alternative 5'-noncoding regions which are spliced to common coding exons. In the present study we use a combination of DNA sequence analysis of the gene, mapping of the mRNA molecules by Northern analysis and
ribonuclease
protection experiments, and DNA sequence analysis of cDNA clones complementary to different regions of the genome to establish the structure of several rIGF-II mRNA species. These results indicate that RNA heterogeneity also arises from the use of different polyadenylation sites. In addition, a variant 2 kilobases RNA was observed that was colinear with the distal 1700 base pairs of the 3147 base pair long exon 3, and may arise by alternative RNA splicing. These posttranscriptional modifications of RNAs arising from the rIGF-II transcription unit may generate molecules with different functional potential.
...
PMID:Structure of the rat insulin-like growth factor II transcriptional unit: heterogeneous transcripts are generated from two promoters by use of multiple polyadenylation sites and differential ribonucleic acid splicing. 322 78
We have found growth-promoting activity for vascular endothelial cells in the conditioned medium of a human lung cancer cell line, T3M-11. Purification and characterization of the growth-promoting activity have been carried out using ammonium sulfate precipitation and gel-exclusion chromatography. The activity migrated as a single peak just after
ribonuclease
. It did not bind to a heparin affinity column. These results suggest that the activity is not a heparin-binding growth factor (including fibroblast growth factors) or a vascular endothelial growth factor. To identify the molecule exhibiting the growth-promoting activity, a cDNA encoding the growth factor was isolated through functional expression cloning in COS-1 cells from a cDNA library prepared from T3M-11 cells. The nucleotide sequence encoded by the cDNA proved to be identical with that of
insulin-like growth factor II
.
...
PMID:Isolation of a cDNA for a growth factor of vascular endothelial cells from human lung cancer cells: its identity with insulin-like growth factor II. 773 Jan 45
Growth and differentiation of the mammary gland during development and lactation are controlled by complex hormonal mechanisms. Additionally growth factors are supposed to act as local mediators of the hormonally controlled developmental processes. Mammary tissue for this study was obtained from non pregnant control heifers, primigravid heifers (second part of pregnancy), around parturition, during lactation (early and late) and from dry cows. Using RT-PCR and
ribonuclease
protections assay (RPA) the expression of the following growth factors was studied in the different phases bovine mammary gland development: Insulin-like growth factor I (IGF-I),
insulin-like growth factor II
(
IGF-II
), fibroblast growth factor 1 (FGF-I), fibroblast growth factor 2 (FGF-2), transforming growth factor alpha (TGF-alpha). Additionally the expression of fibroblast growth factor receptor (FGFR) and growth hormone receptor (GHR) was investigated. The cellular distribution pattern of several of these growth factors and GHR was obtained using Immunocytochemical techniques. The detailed expression and localization pattern of these growth factors are presented and their role in the local regulation of the bovine mammary gland is briefly discussed.
...
PMID:Expression and localization of growth factors during mammary gland development. 1095 6